Brain cancer update

Brain cancer update July 12, 2024
Leanna Standish

IV CURCUMIN

AIMS Institute’s integrative oncology team is investigating the therapeutic effects of intravenous curcumin in treating the most aggressive type of brain cancer, called glioblastoma. Curcumin is the molecule present in turmeric root that has anticancer activity. Curcumin has been shown in cell culture experiments to cause the programmed death of glioblastoma cells. We use IV curcumin in order to provide sufficient levels of curcumin to the brain that will slow tumor growth. Our brain cancer patients are enrolled in AIMS Institute’s IRB-approved study called the AIMS CANCER OUTCOMES STUDY. Last year we presented our first results of IV curcumin in glioblastoma to the SWEDISH HOSPITAL NEUROLOGY SEMINAR and at the ONCOLOGY ASSOCIATION OF NATUROPATHIC ONCOLOGY annual meeting.

Currently, Drs. Jaffe, Anthony, and Standish are preparing a scientific manuscript for a medical journal that summarizes our findings.

LIQUID BIOPSY IS NOW AVAILABLE FOR BRAIN CANCER

AIMS Institute utilizes cutting-edge cancer genetic sequencing to help us understand the unique biology of each patient’s cancer. Liquid biopsy refers to a blood test that sequences the DNA in tumor cells that circulate in the blood. Until 2024 there has never been a liquid biopsy for brain cancer. Thanks to BILLION TO ONE a cancer gene company there is now a blood test for brain cancer. These blood tests help us know what the best treatment might be and also whether the current treatment is working for the patient.

Latest Blog Posts

Stellate Ganglion Block Effectiveness for PTSD, Anxiety, and Depression in Psychiatric Outpatients: A Retrospective Analysis

https://scholarworks.seattleu.edu/dnp-projects/166/ The prevalences of Post-Traumatic Stress Disorder (PTSD), generalized anxiety disorder (GAD), and major depressive disorder (MDD) have risen significantly in recent years, particularly following the COVID-19 pandemic. Many individuals remain symptomatic despite conventional treatments, highlighting the need for novel, integrative interventions. Stellate Ganglion Block (SGB), a procedure targeting the cervical sympathetic chain to modulate the autonomic nervous system, has emerged as a promising therapy for treatment-resistant psychiatric symptoms. Evaluating data from the PTSD Checklist for DSM-5 (PCL-5), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9), this retrospective study examined the clinical outcomes of PTSD, anxiety, and depression symptoms ...

BEWARE OF CANCER MISINFORMATION

Our AIMS Institute oncology team is well informed about alternative cancer therapies such as ivermectin, intravenous vitamin C, mistletoe, curcumin, and mebendazole. We help our patients sort through marketing hype, wishful thinking, and the real value of some alternative treatments. We say to our cancer patients who do not trust conventional medicine to beware of misinformation on the internet. Be discerning. We can help. Here is a recent MEDSCAPE article on this topic. ...

AIMS INSTITUTE’S COGNITIVE DECLINE PROTOCOL

LJ STANDISH AND DAVID JAMES Dr. Standish and her team can help improve brain function, improve memory and slow cognitive decline in Alzheimer’s disease. Please make an appointment to start. Call 206-420-1321. Scientific Rationale A protocol incorporating low-dose lithium orotate, Lion’s Mane mushroom extract, NADH, transcranial magnetic stimulation (TMS), and blood sugar regulation counseling is scientifically rational for treating cognitive decline based on mechanistic, preclinical, and emerging human studies. Low-Dose Lithium Orotate (5 mg/day) Recent brain tissue studies link low brain lithium to the onset and progression of Alzheimer’s disease, with deficiency accelerating synaptic loss and cognitive decline. Low-dose lithium orotate has ...